AI tools are revolutionizing neuroscience, enabling researchers to predict study outcomes with 86% accuracy and uncover novel ...

Michael W. Schwartz UW Medicine Diabetes Institute, explains how the brain can be targeted to treat obesity and diabetes ...

You will be redirected to our submission process. We are delighted to present the inaugural “Horizons in Computational Neuroscience” article collection. This collection showcases high-impact, ...

Neuroscience is a multidisciplinary science that is concerned with the study of the structure and function of the nervous system. It encompasses the evolution, development, cellular and molecular ...

We encourage scientists who share our view on the revolutionary role of nanotechnology for Neuroscience to submit their manuscripts to this research topic. We welcome a variety of article types: ...

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

The M.Sc. in Neuroscience studies the functioning of the nervous system at all levels, from the molecules that make up individual nerve cells, to the complexities of animal and human behaviour. A ...

The materials may also have applications in other areas of neuroscience, such as combatting neurodegenerative disease, Khanbareh explained: “Coupling these materials with bioelectronics may enable ...

Social neuroscience is a research discipline that examines how the brain mediates social processes and behaviour. A wide range of research topics are examined within this discipline, including ...

Recent discoveries in neuroscience have shown that our brains change rapidly during our teenage years and continue to develop until our mid-twenties. Every teenager has a unique experience ...

Figure 1: The primary Zang Organs and their corresponding emotions. Western neuroscience has discovered aspects of the heart that confirm this thousand-year-old Chinese medical concept. Dr. Armour ...

Vigil Neuroscience, Inc. has announced its plans to report data from its Phase 1 clinical trial of VG-3927, a TREM2 agonist for Alzheimer’s disease, in the first quarter of 2025, and expects to ...